Dr Susan Bal speaks to ecancer about redefining RRMM treatment with CAR-T cell therapy.

Chimeric antigen receptor T-cell therapies significantly enhance treatment outcomes for relapsed multiple myeloma.

Pivotal studies show improved progression-free survival rates, leading to FDA approvals for ide-cel and cilta-cel.

The KARMMA-3 trial highlights substantial patient outcome improvements.

While these therapies offer transformative efficacy, challenges like access and unique toxicities remain.

Understanding the risk of secondary malignancies is essential as these therapies move into earlier treatment lines.